Drug Profile
Zodasiran - Arrowhead Pharmaceuticals
Alternative Names: ARO-ANG3; VSA-003Latest Information Update: 17 Nov 2023
Price :
$50
*
At a glance
- Originator Roche
- Developer Arrowhead Pharmaceuticals
- Class Antihyperlipidaemics; Cardiovascular therapies; Small interfering RNA
- Mechanism of Action ANGPTL3 protein expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Dyslipidaemias; Hyperlipoproteinaemia type II
Most Recent Events
- 13 Nov 2023 Adverse events and efficacy data from a phase II trial in Dyslipidaemias released by Arrowhead Pharmaceuticals
- 11 Nov 2023 Updated adverse events and efficacy data from the phase-II ARCHES-2 trial in Dyslipidaemias presented at the American Heart Association Scientific Sessions (AHA-2023)
- 23 May 2023 Arrowhead Pharmaceuticals intends to conduct a meeting with regulatory authorities in the second half of 2023